Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413036 · ClinicalTrials.gov registry record · Phase 2
A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 217
- Enrollment target
NCT00413036 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 217 participants.
The verdict
NCT00413036, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 217 participants
- Enrollment target
Study Summary
Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop
Interventions
- DRUG lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2006-06 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00413036
The ClinicalTrials.gov registry entry for NCT00413036 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lenalidomide is the first listed.
NCT00413036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00413036 about?
NCT00413036 is a clinical study titled "A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma". Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop
What is the current status of trial NCT00413036?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 217 participants. The study started on 2006-06. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00413036?
The interventions under investigation include: lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00413036?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.